• Todd Hollon, Sandra I Camelo-Piragua, Erin L McKean, Stephen E Sullivan, and Hugh J L Garton.
• Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA.
• World Neurosurg. 2016 Mar 1; 87: 661.e5-12.

Background And ImportanceRosai-Dorfman disease is a rare benign histiocytic proliferative disorder with a self-limiting clinical course. Skull base Rosai-Dorfman disease presents with intracranial lesions that often mimic meningiomas and other benign skull base tumors. The disease is difficult to diagnose radiographically, and tissue diagnosis exposes patients to significant perioperative risk. Surgical resection may require a large skull base exposure that risks significant surgical morbidity. Aggressive surgical resection, although often attempted, is of unproven efficacy. Our objective was to determine the optimal surgical management of skull base Rosai-Dorfman disease.Case DescriptionWe present 2 cases of skull base Rosai-Dorfman disease: a 26-year-old man with a middle fossa tumor and a 15-year-old teenage girl with a hypothalamic tumor. In addition, we reviewed 39 cases of skull base Rosai-Dorfman disease reported in the literature.ConclusionsTumors commonly occur in the sellar/parasellar region and result in loss of vision. Regardless of extent of resection, the majority of patients (>78%) have subsequent tumor regression or stable disease. Steroids and/or radiation are effective treatments for tumor recurrence. Tumor biopsy followed by observation, steroids, and/or radiation may be the most appropriate surgical management of skull base Rosai-Dorfman disease.Copyright © 2016 Elsevier Inc. All rights reserved.

31 keywords...

hide…